Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Trading of Depomed Common Stock Halted
Advisory Committee of the Food and Drug Administration to Discuss SEFELSA™ New Drug Application for the Treatment of Moderate to Severe Vasomotor Symptoms Conference Call Later Today NEWARK, Calif. , March 4, 2013 /PRNewswire/ --  Depomed, Inc. (NASDAQ:DEPO) announced that NASDAQ has halted trading
Toggle Summary THE MICHAEL J. FOX FOUNDATION AWARDS DEPOMED A SECOND DEVELOPMENT GRANT IN PARKINSON'S DISEASE
MENLO PARK, Calif. - October 11, 2010 - Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a clinical grant by The Michael J. Fox Foundation under its Clinical Intervention Awards 2010 program.  The modest grant amount supports Depomed in the development of a gastric retentive
Toggle Summary The Michael J. Fox Foundation Awards Depomed a Preclinical Development Grant for Levodopa/Carbidopa in Parkinson's Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--July 23, 2008--Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a preclinical grant by The Michael J. Fox Foundation under the foundation's Therapeutics Development Initiative 2008 Program. The modest grant amount supports Depomed in the

Recent SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

EFFECT

EFFECT
Other
View HTML

Amendment to a previously filed 8-K

8-K/A
Current Reports
View HTML

8-K12B

8-K12B
Other
View HTML

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com